Tumor cells with genetic amplifications or mutations in the fibroblast growth factor receptor (FGFR) family are often addicted to FGFR and heavily dependent on its signaling to survive. Although it is critical to understand which signaling pathway downstream of FGFR plays an essential role to guide the research and development of FGFR inhibitors, it has remained unclear partly because the tool compounds used in the literature also hit many other kinases, making the results difficult to interpret. With the development of a potent FGFR-specific inhibitor, BGJ398, we are now able to dissect various pathways with low drug concentrations to minimize multiple-target effects. Importantly, here, we show that inhibition of FGFR signaling by BGJ398 leads to only transient inhibition of ERK1/2 phosphorylation, whereas the inhibitory effect on AKT phosphorylation is sustainable, indicating that AKT, not ERK as commonly believed, serves as an appropriate pharmacodynamic biomarker for BGJ398. Although AKT inhibition by a pan-PI3K inhibitor alone has almost no effect on cell growth, heterologous expression of myr-AKT, an active form of AKT, rescues BGJ398-mediated suppression of tumor cell proliferation. These results indicate that AKT is an essential component downstream of FGFR. Finally, combination of the FGFR inhibitor BGJ398 with rapamycin significantly inhibits AKT phosphorylation and enhances their antiproliferative effects in FGFR-addicted cells, suggesting an effective combination strategy for clinical development of FGFR inhibitors.
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Introduction
The fibroblast growth factor receptor (FGFR) family, comprising four members (FGFR1, FGFR2, FGFR3, and FGFR4), is an attractive group of therapeutic targets being actively pursued in oncology [1] . Each receptor consists of an extracellular ligand-binding domain, a transmembrane domain, and a cytosolic region with tyrosine kinase function. FGFR family members serve as high-affinity receptors for the fibroblast growth factors (FGFs) involved in cell proliferation, migration, and apoptosis.
FGFR and its ligands, FGFs, are deregulated in many types of tumors. Amplification and active mutations in FGFR3 and FGFR2 have been identified in solid tumors, including bladder carcinomas, gastric cancer, and endometrial carcinomas [2] [3] [4] . It has also been reported that translocation and fusion of FGFR3 to other genes are associated with peripheral T-cell lymphoma and multiple myeloma [5] . By and large, FGFR is essential in cell lines with constitutively active FGFR signaling and its inhibition generally leads to cell death, known as FGFR dependent or FGFR addicted [6] .
A number of small-molecule FGFR inhibitors have entered clinical development. These compounds include TKI258, BMS-582664, and AZD2171, targeting not only FGFR but also other kinases, such as VEGFRs, FLT3, c-KIT, and others (for an updated list of compounds in clinical trial, see Table 1 ) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Recently, BGJ398 has been discovered as a potent, orally bioavailable, and specific small-molecule inhibitor of FGFR. BGJ398 significantly inhibits the proliferation of cancer cell lines bearing FGF/FGFR genetic alterations across various cancer types [10, 17] . It is currently in a clinical phase I trial.
Although inhibition of cell proliferation by FGFR-specific inhibitors such as BGJ398 has been validated preclinically, the mechanism of downstream signal transduction has not been well studied. Such information would be critical for the development of appropriate pharmacodynamic (PD) biomarker assays for FGFR inhibitors and rational strategies for combining FGFR inhibitors with other small-molecule inhibitors to improve chemotherapeutic efficacies with minimized toxicity. In this study, BGJ398 was used as a powerful research tool for dissecting the signaling pathways in FGFR-dependent cell lines. Subsequently, a combination of BGJ398 with a mammalian target of rapamycin (mTOR) inhibitor was tested in cancer cell lines. Our study may offer new insights into FGFR signaling and provide potentially more potent small-molecule chemotherapeutic drugs.
Materials and methods

Compounds and antibodies
BGJ398 and GDC-0941 were purchased from Selleck (Houston, Texas, USA). For in-vitro studies, 10 mmol/l stock solutions were prepared in 100% dimethyl sulfoxide (DMSO). Antibodies used for western blot analysis were from Cell Signaling (anti-S473P-AKT, anti-AKT, anti-T202P/ Y204P-ERK1/2, anti-ERK1/2, anti-MET, anti-FRS2, anti-Rb; Boston, Massachusetts, USA) and from Sigma (anti-actin; St Louis, Missouri, USA).
Cell proliferation assay
Cells were seeded in 96-well plates at a density of 10 3 -10 4 cells/well in a volume of 100 ml. After 24 h, media containing test compounds (such as BGJ398) or DMSO were added. Following 72 h of incubation, CellTiter-Glo (Promega, Madison, Wiconsin, USA) was added. The concentration of BGJ398 resulting in 50% inhibition of proliferation (IC 50 ) was determined using XLfit (Microsoft, Redmond, Washington, USA).
Western blot analysis
Cell extracts were prepared in RIPA buffer containing phosphatase and protease inhibitors. Equal amounts of proteins, as measured by a BCA assay, were resolved on 4-12% gradient gels and transferred to a nitrocellulose membrane using the iBlot system (Invitrogen, New York, New York, USA). After blocking in TBST with 5% nonfat milk, the membranes were probed with primary antibodies. Bound proteins were detected with IRDye 800CW-conjugated goat anti-rabbit IgG, or IRDye 680-conjugated goat anti-mouse IgG using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, Nebraska, USA).
Results
BGJ398 modulates multiple signaling proteins
KATO III is a gastric cancer cell line with high levels of FGFR2 gene expression. BGJ398 has a low nanomolar IC 50 for KATO III cells ( Fig. 1) , thus allowing treatment with low concentration to avoid complications arising from simultaneously targeting other kinases. Two concentrations of BGJ398, 10 nmol/l (IC 40 ) and 100 nmol/l (IC 90 ), were used in the following experiments.
The effects of BGJ398 on FGFR signaling were first examined by analyzing the expression and phosphorylation level of AKT and ERK1/2 (Fig. 2) . KATO III cells were collected at 2, 8, and 24 h following BGJ398 treatment for western blot analysis (Fig. 2a) . Although the total ERK1/2 levels remained unchanged, pERK1/2 levels were decreased after 2 h of treatment with BGJ398, suggesting that ERK1/2 is involved in FGFR signaling. In contrast to previous studies with primarily short-term FGFR inhibition [17] , we extended BGJ398 treatment of KATO III cells to 24 h and found that the downregulation effect on pERK1/2 was partially reversed by 8 h after BGJ398 treatment. The inhibition of pERK1/2 by BGJ398 was completely abolished by 24 h after treatment, suggesting that a strong negative feedback effect on ERK1/2 phosphorylation was induced following FGFR inhibition. This finding thus challenged the notion that downregulated pERK1/2 is an ideal PD biomarker for FGFR inhibitors. In contrast to pERK1/2, we found that BGJ398 strongly inhibited AKT phosphorylation in KATO III cells, starting from 2 h through the course of treatment up to 3 days (Fig. 2a and data not shown) . The sustained downregulation of pAKT suggested that pAKT may be a better PD marker for FGFR inhibitors than pERK1/2. In addition to KATO III cells, we have found a slower but similar pattern of BGJ398-mediated dynamic changes of pERK1/2 and constant suppression of pAKT levels in other FGFR-dependent cell lines, such as RT112 cells (Fig. 2b) .
Furthermore, we examined FRS2 phosphorylation and protein levels of cell cycle regulators and other signaling components. Upon BGJ398 treatment, FRS2 phosphorylation remained inhibited throughout the course of the study, indicating the effectiveness of the compound (Fig. 2c) . The levels of the cell cycle regulator RB showed little change at 2 h, but started to decrease at 8 h and more significantly at 24 h. In addition, p27 showed a similar time-dependent change in protein levels, whereas levels of other proteins such as pMET, STAT3, STAT5, and p38 were relatively unchanged upon BGJ398 treatment ( Fig. 2c and data not shown ).
An active form of AKT rescues BGJ398-mediated suppression of tumor cell growth AKT phosphorylation is a prerequisite to AKT activation [18] . As AKT phosphorylation was suppressed by BGJ398 in KATO III cells, we next asked whether an active form of AKT could counteract the inhibitory effects of tumor cell growth elicited by BGJ398. In this study, we used myr-AKT, an active form of AKT that is myristoylated and directly associated with plasma membrane [19] . To examine the effect of myr-AKT, we transfected a myr-AKT construct into KATO III cells, followed by BGJ398 treatment. As shown in Fig. 3a , myr-AKT considerably rescued BGJ398-mediated suppression of KATO III cell growth, suggesting that the activity of AKT is important for the inhibitory effects of FGFR inhibitors on tumor cells. In the absence of FGFR inhibitors, however, inhibition of AKT activity alone may not be sufficient for killing tumor cells. When we treated KATO III cells with a pan-PI3K inhibitor that suppresses AKT phosphorylation [20] , there was almost no difference in cell proliferation between treated and untreated cells (Fig. 3b) . Taken together, these data indicate that a decrease in AKT phosphorylation is essential, but not sufficient, for BGJ398-mediated suppression of tumor cell growth. Therefore, signaling pathways that compensate for AKT inactivation remain to be explored for a better understanding of the biology of BGJ398 and clinical development of FGFR inhibitors.
Enhanced killing of tumor cells with a combination of BGJ398 and rapamycin mTOR is a well-known downstream target of AKT [21] . Recently, a negative feedback loop has been proposed as a compensatory mechanism underlying the limited efficacy of AKT/mTOR inhibition [22, 23] . We hypothesized that AKT inactivation, when coupled with mTOR inhibitors, may provide improved therapeutic efficacy. In this study, a natural product, rapamycin, was chosen as an allosteric inhibitor of mTOR [24] . Rapamycin alone exerted a relatively weak effect on the proliferation of KATO III cells with IC 50 greater than 1 mmol/l. However, a combination of rapamycin and BGJ398 in the low nmol/l range significantly suppressed the growth of KATO III cells (Fig. 4a) . Similarly, the synergistic effects of rapamycin and BGJ398 in the 10-100 nmol/l range were also observed in RT112 cells (Fig. 4b) , which is a bladder cancer cell line with high levels of FGFR3 gene expression [25] . We further tested the effects of combinations on AKT and ERK signaling in KATO III and RT112 cells treated with BGJ398 and rapamycin at low concentrations or in combination. As shown in Fig. 4c , AKT phosphorylation was decreased slightly in both cells when treated with low concentrations of BGJ398 or rapamycin alone and it was significantly inhibited when treated with combinations. ERK phosphorylation was decreased only in RT112 cells, not in KATO III cells, when the two compounds were combined. In contrast to the BGJ398/rapamycin pair, there were no synergistic effects between BGJ398 and PI3K inhibitors in KATO III cells or RT112 cells (data not shown). These data suggest that the inhibition of FGFR and mTOR simultaneously enhances the potency of FGFR or mTOR inhibitors against tumor cell proliferation.
Discussion
Although others have reported that inhibition of FGFR by specific inhibitors reduced pERK1/2 levels and used it as a PD biomarker, those data were usually generated in a very short period of time (typically < 3 h). In this study, our results indicate that although reduction of pERK1/2 levels is significant at an early stage of FGFR inhibition, the downregulation effect is reversed by continuous treatment of two cell lines, KATO III and RT112, with the FGFR inhibitor BGJ398. These results suggest that a negative feedback loop may exist, which accounts for compensatory post-translational modifications of proteins when cells are challenged with FGFR inhibitors. Such negative feedback loops have been reported previously to be associated with other kinase inhibitors, including BRAF inhibitors [26] and mTOR inhibitors [22, 23] . The presence of negative feedback loops has considerably impeded the clinical development of kinase inhibitors. In this respect, the complex nature of signal transduction in biology poses a huge challenge for translating basic research into clinical medicine [27] [28] [29] [30] .
Unlike pERK1/2, pAKT remained stably repressed in KATO III cells during a 24-h treatment with BGJ398. Therefore, pAKT, rather than pERK1/2, could be a more appropriate PD biomarker for FGFR inhibitors. Furthermore, our data showed that although an active form of AKT, myr-AKT, could rescue BGJ398-mediated suppression of KATO III cell growth, inhibition of AKT phosphorylation by a pan-PI3K inhibitor had almost no effect on cell proliferation. These findings suggest that AKT inactivation is essential, but not sufficient, for BGJ398-induced suppression of tumor cell growth. In addition to AKT, our data also showed that BGJ398 could modulate proteins in multiple signaling pathways, including cell cycle regulators RB. Although the phosphorylation of ERK1/2 was only transiently repressed by BGJ398, we cannot completely rule out an important role for the ERK1/2 pathway in FGFR inhibition. It remains possible that a transient inhibition of ERK1/2 phosphorylation could induce irreversible changes in cellular signal transduction. This hypothesis could be tested with specific MEK inhibitors that can potently inhibit ERK1/2 phosphorylation. However, the success of such studies will still rely heavily on the PD properties of the MEK inhibitors, especially how fast they can block ERK1/2 signaling once the cells are treated, and how quickly the effect can be eliminated when the inhibitors are removed, to mimic the transient inhibitory effect of BGJ398.
Finally, on the basis of BGJ398-induced stable repression of AKT phosphorylation, we tested and confirmed the synergistic effects of BGJ398 and the mTOR inhibitor rapamycin in two types of tumor cells: KATO III and RT112. We found that AKT phosphorylation was impaired significantly in both cell lines treated with combinations of BGJ398 and rapamycin compared with cells treated with a single agent. ERK phosphorylation was changed inconsistently in these two cell lines. These data suggested that AKT signaling could be one of the downstream pathways when both FGFR and mTOR were inhibited. GDC-9041 was a pan-PI3K inhibitor, which strongly inhibited AKT phosphorylation as well as BGJ398 did (data not shown). There was little synergistic effect when BGJ398 and GDC-9041 were combined, suggesting that inhibition of AKT signaling alone was not able to account for the combination effects between BGJ398 and rapamycin. Further investigation is warranted to determine the effects of these kinase inhibitor cocktails in other FGFR-addicted cell lines. We envisage that simultaneous inhibition of multiple kinase targets will considerably improve the therapeutic efficacy of kinase inhibitors.
